{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:38:42Z","timestamp":1790487522528,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.leukres.2024.107596","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T06:27:22Z","timestamp":1727418442000},"page":"107596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Chemotherapy and allo-HSCT for young patients with aggressive ATL"],"prefix":"10.1016","volume":"147","author":[{"given":"Shigeo","family":"Fuji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.leukres.2024.107596_bib1","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","article-title":"Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma","volume":"15","author":"Ishitsuka","year":"2014","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2024.107596_bib2","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1200\/JCO.18.00501","article-title":"Revised adult T-cell leukemia-lymphoma international consensus meeting report","volume":"37","author":"Cook","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2024.107596_bib3","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s12185-019-02602-4","article-title":"Clinical features at transformation in adult T-cell leukemia-lymphoma with smoldering and chronic types","volume":"109","author":"Taniguchi","year":"2019","journal-title":"Int. J. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2024.107596_bib4","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3324\/haematol.2017.164996","article-title":"Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation","volume":"102","author":"Fuji","year":"2017","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.leukres.2024.107596_bib5","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/s41409-019-0446-z","article-title":"VCAP-AMP-VECP as a preferable induction chemotherapy in transplant-eligible patients with aggressive adult T-cell leukemia-lymphoma: a propensity score analysis","volume":"54","author":"Fuji","year":"2019","journal-title":"Bone Marrow Transpl."},{"issue":"34","key":"10.1016\/j.leukres.2024.107596_bib6","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2024.107596_bib7","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/j.clml.2020.03.008","article-title":"Efficacy and safety of the modified EPOCH regimen (Etoposide, Vincristine, Doxorubicin, Carboplatin, and Prednisolone) for Adult T-cell Leukemia\/Lymphoma: a multicenter retrospective study","volume":"20","author":"Tsukamoto","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"4","key":"10.1016\/j.leukres.2024.107596_bib8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1182\/blood.2019004045","article-title":"How I treat adult T-cell leukemia\/lymphoma","volume":"137","author":"Cook","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2024.107596_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12985-023-02077-0","article-title":"Zidovudine and Interferon Alfa based regimens for the treatment of adult T-cell leukemia\/lymphoma (ATLL): a systematic review and meta-analysis","volume":"20","author":"Shafiee","year":"2023","journal-title":"Virol. J."},{"issue":"3","key":"10.1016\/j.leukres.2024.107596_bib10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15123","article-title":"Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation","volume":"184","author":"Ishida","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.leukres.2024.107596_bib11","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"28","key":"10.1016\/j.leukres.2024.107596_bib12","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","article-title":"Pretransplantation anti-CCR4 antibody Mogamulizumab against adult T-Cell Leukemia\/Lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality","volume":"34","author":"Fuji","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107596_bib13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.21037\/sci.2016.09.13","article-title":"Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia\/lymphoma","volume":"3","author":"Fuji","year":"2016","journal-title":"Stem Cell Invest."},{"issue":"9","key":"10.1016\/j.leukres.2024.107596_bib14","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.bbmt.2016.05.017","article-title":"Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease","volume":"22","author":"Sugio","year":"2016","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"5","key":"10.1016\/j.leukres.2024.107596_bib15","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.12962","article-title":"Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A)","volume":"166","author":"Fukushima","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.leukres.2024.107596_bib16","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.bbmt.2020.04.019","article-title":"Clinical outcomes of patients with adult T Cell Leukemia-Lymphoma in a nonendemic metropolitan area: a retrospective analysis of the population-based osaka cancer registry","volume":"26","author":"Fuji","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"1","key":"10.1016\/j.leukres.2024.107596_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00277-020-04308-8","article-title":"Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma-not otherwise specified with limited improvement in overall survival: a retrospective analysis using data from the population-based Osaka Cancer Registry","volume":"100","author":"Fuji","year":"2021","journal-title":"Ann. Hematol."},{"issue":"12","key":"10.1016\/j.leukres.2024.107596_bib18","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1111\/cas.14658","article-title":"Prognosis of patients with adult T-cell leukemia\/lymphoma in Japan: a nationwide hospital-based study","volume":"111","author":"Imaizumi","year":"2020","journal-title":"Cancer Sci."},{"issue":"14","key":"10.1016\/j.leukres.2024.107596_bib19","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","article-title":"Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma","volume":"30","author":"Katsuya","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.leukres.2024.107596_bib20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1159\/000534040","article-title":"Poor outcome of adult T-Cell leukemia\/lymphoma with current available therapy: an experience of two centers","volume":"46","author":"Saeed","year":"2023","journal-title":"Oncol. Res. Treat."},{"issue":"2-3","key":"10.1016\/j.leukres.2024.107596_bib21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s44228-023-00032-y","article-title":"Outcome of stem cell transplantation in htlv-1-associated north american adult T-cell leukemia\/lymphoma","volume":"5","author":"Bazarbachi","year":"2023","journal-title":"Clin. Hematol. Int."},{"issue":"10","key":"10.1016\/j.leukres.2024.107596_bib22","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/bmt.2014.143","article-title":"Outcome of patients with HTLV-1-associated adult T-cell leukemia\/lymphoma after SCT: a retrospective study by the EBMT LWP","volume":"49","author":"Bazarbachi","year":"2014","journal-title":"Bone Marrow Transpl."},{"issue":"8","key":"10.1016\/j.leukres.2024.107596_bib23","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.bbmt.2019.05.027","article-title":"Efficacy of allogeneic HEmatopoietic Cell Transplantation in human T cell lymphotropic virus Type 1-associated adult T cell leukemia\/lymphoma: results of a systematic review\/meta-analysis","volume":"25","author":"Iqbal","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"5","key":"10.1016\/j.leukres.2024.107596_bib24","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2403682","article-title":"Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia\/lymphoma","volume":"19","author":"Fukushima","year":"2005","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2024.107596_bib25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bbmt.2006.09.002","article-title":"Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia\/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program","volume":"13","author":"Kato","year":"2007","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"9","key":"10.1016\/j.leukres.2024.107596_bib26","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/s41409-023-02002-7","article-title":"Impact of HLA-mismatched unrelated transplantation in patients with adult T-cell leukemia\/lymphoma","volume":"58","author":"Inoue","year":"2023","journal-title":"Bone Marrow Transpl."},{"issue":"16_suppl","key":"10.1016\/j.leukres.2024.107596_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.7001","article-title":"Upfront allo-HSCT after intensive chemotherapy for untreated aggressive ATL: JCOG0907, a single-arm, phase 3 trial","volume":"42","author":"Fukushima","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.leukres.2024.107596_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2013.57","article-title":"Association between decreasing trend in the mortality of adult T-cell leukemia\/lymphoma and allogeneic hematopoietic stem cell transplants in Japan: analysis of Japanese vital statistics and Japan Society for Hematopoietic Cell Transplantation (JSHCT)","volume":"3","author":"Chihara","year":"2013","journal-title":"Blood Cancer J."},{"issue":"12","key":"10.1016\/j.leukres.2024.107596_bib29","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.bbmt.2013.09.014","article-title":"Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study","volume":"19","author":"Ishida","year":"2013","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"9","key":"10.1016\/j.leukres.2024.107596_bib30","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1182\/blood-2011-07-368233","article-title":"Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study","volume":"119","author":"Kanda","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2024.107596_bib31","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41409-023-01969-7","article-title":"The clinical benefit of acute GVHD depends on the age at transplantation in patients with adult T-cell leukemia-lymphoma on behalf of the ATL working group of the japan society for transplantation and cellular therapy","volume":"58","author":"Fuji","year":"2023","journal-title":"Bone Marrow Transpl."},{"issue":"1","key":"10.1016\/j.leukres.2024.107596_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.beha.2013.04.001","article-title":"Biology and treatment of HTLV-1 associated T-cell lymphomas","volume":"26","author":"Tsukasaki","year":"2013","journal-title":"Best. Pr. Res. Clin. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2024.107596_bib33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/bmt.2015.265","article-title":"Early application of related SCT might improve clinical outcome in adult T-cell leukemia\/lymphoma","volume":"51","author":"Fuji","year":"2016","journal-title":"Bone Marrow Transpl."},{"issue":"7","key":"10.1016\/j.leukres.2024.107596_bib34","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41409-017-0082-4","article-title":"Role of up-front allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma: a decision analysis","volume":"53","author":"Fuji","year":"2018","journal-title":"Bone Marrow Transpl."},{"issue":"4","key":"10.1016\/j.leukres.2024.107596_bib35","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s12185-013-1307-y","article-title":"Feasibility of cord blood transplantation in chemosensitive adult T-cell leukemia\/lymphoma: a retrospective analysis of the Nagasaki Transplantation Network","volume":"97","author":"Fukushima","year":"2013","journal-title":"Int. J. Hematol."},{"issue":"5","key":"10.1016\/j.leukres.2024.107596_bib36","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s12185-012-1177-8","article-title":"Unrelated cord blood transplantation for patients with adult T-cell leukemia\/lymphoma: experience at a single institute","volume":"96","author":"Nakamura","year":"2012","journal-title":"Int. J. Hematol."},{"issue":"3","key":"10.1016\/j.leukres.2024.107596_bib37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s12185-019-02777-w","article-title":"A decision analysis comparing unrelated bone marrow transplantation and cord blood transplantation in patients with aggressive adult T-cell leukemia-lymphoma","volume":"111","author":"Fuji","year":"2020","journal-title":"Int. J. Hematol."},{"issue":"8","key":"10.1016\/j.leukres.2024.107596_bib38","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","article-title":"Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study","volume":"116","author":"Hishizawa","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2024.107596_bib39","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/s41409-018-0400-5","article-title":"A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia-lymphoma","volume":"54","author":"Yoshimitsu","year":"2019","journal-title":"Bone Marrow Transpl."},{"issue":"12","key":"10.1016\/j.leukres.2024.107596_bib40","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.bbmt.2014.08.012","article-title":"Treatment of patients with adult T cell leukemia\/lymphoma with cord blood transplantation: a Japanese nationwide retrospective survey","volume":"20","author":"Kato","year":"2014","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"20","key":"10.1016\/j.leukres.2024.107596_bib41","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1182\/bloodadvances.2021004932","article-title":"Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study","volume":"5","author":"Ito","year":"2021","journal-title":"Blood Adv."},{"issue":"11","key":"10.1016\/j.leukres.2024.107596_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.07.010","article-title":"A phase I\/II multicenter trial of HLA-haploidentical PBSCT with PTCy for aggressive adult T cell leukemia\/lymphoma","volume":"27","author":"Tanaka","year":"2021","journal-title":"Transpl. Cell Ther."},{"issue":"4","key":"10.1016\/j.leukres.2024.107596_bib43","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41409-023-01919-3","article-title":"Cord blood is a suitable donor source of allogeneic hematopoietic cell transplantation for adult T-cell leukemia-lymphoma: a nationwide retrospective study","volume":"58","author":"Tokunaga","year":"2023","journal-title":"Bone Marrow Transpl."},{"issue":"9","key":"10.1016\/j.leukres.2024.107596_bib44","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1080\/10428194.2021.1897806","article-title":"Outcomes of adult T-Cell leukemia\/lymphoma with allogeneic stem cell transplantation: single-institution experience","volume":"62","author":"Epstein-Peterson","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"8","key":"10.1016\/j.leukres.2024.107596_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9082417","article-title":"Allogeneic stem cell transplantation for adult T-cell leukemia\/lymphoma-romanian experience","volume":"9","author":"Tanase","year":"2020","journal-title":"J. Clin. Med."},{"issue":"8","key":"10.1016\/j.leukres.2024.107596_bib46","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2012-03-414490","article-title":"Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study","volume":"120","author":"Ishida","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2024.107596_bib47","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2004-11-4193","article-title":"Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia\/lymphoma","volume":"105","author":"Okamura","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2024.107596_bib48","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/bmt.2010.92","article-title":"Long-term outcomes after hematopoietic SCT for adult T-cell leukemia\/lymphoma: results of prospective trials","volume":"46","author":"Choi","year":"2011","journal-title":"Bone Marrow Transpl."},{"issue":"12","key":"10.1016\/j.leukres.2024.107596_bib49","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1038\/s41409-021-01445-0","article-title":"Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma","volume":"56","author":"Inoue","year":"2021","journal-title":"Bone Marrow Transpl."},{"issue":"5","key":"10.1016\/j.leukres.2024.107596_bib50","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2017.184564","article-title":"Outcomes of patients with relapsed aggressive adult T-cell leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation","volume":"103","author":"Fuji","year":"2018","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.leukres.2024.107596_bib51","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/bmt.2016.313","article-title":"Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia\/lymphoma, a Japanese nation-wide study","volume":"52","author":"Fujiwara","year":"2017","journal-title":"Bone Marrow Transpl."},{"issue":"4","key":"10.1016\/j.leukres.2024.107596_bib52","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.bbmt.2014.12.020","article-title":"A retrospective analysis of treatment outcomes in adult T cell leukemia\/lymphoma patients with aggressive disease treated with or without allogeneic stem cell transplantation: a single-center experience","volume":"21","author":"Kawada","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"2","key":"10.1016\/j.leukres.2024.107596_bib53","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12185-018-2455-x","article-title":"EPOCH regimen as salvage therapy for adult T-cell leukemia-lymphoma","volume":"108","author":"Toriyama","year":"2018","journal-title":"Int. J. Hematol."},{"issue":"5","key":"10.1016\/j.leukres.2024.107596_bib54","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3324\/haematol.2018.205096","article-title":"Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed\/refractory adult T-cell leukemia\/lymphoma","volume":"104","author":"Phillips","year":"2019","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.leukres.2024.107596_bib55","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2024.107596_bib56","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.19231","article-title":"A treatment strategy to mitigate the adverse effect of pretransplant mogamulizumab on post-transplant clinical outcome in patients with aggressive ATL","volume":"204","author":"Fuji","year":"2024","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.leukres.2024.107596_bib57","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12185-021-03250-3","article-title":"Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation","volume":"115","author":"Inoue","year":"2022","journal-title":"Int. J. Hematol."},{"issue":"34","key":"10.1016\/j.leukres.2024.107596_bib58","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-Cell leukemia\/lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2024.107596_bib59","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.2022016862","article-title":"An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma","volume":"141","author":"Izutsu","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2024.107596_bib60","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1111\/cas.15431","article-title":"Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia\/lymphoma: phase IIb results","volume":"113","author":"Utsunomiya","year":"2022","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.leukres.2024.107596_bib61","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(15)00284-7","article-title":"Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study","volume":"3","author":"Ogura","year":"2016","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2024.107596_bib62","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hon.2558","article-title":"The outcome and characteristics of patients with relapsed adult T cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation","volume":"37","author":"Kato","year":"2019","journal-title":"Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2024.107596_bib63","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2012-07-444372","article-title":"Treatment of relapsed adult T-cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience","volume":"121","author":"Itonaga","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2024.107596_bib64","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12185-022-03447-0","article-title":"Mogamulizumab for post-transplant relapse of adult T-cell leukemia\/lymphoma: a case study","volume":"117","author":"Hirosawa","year":"2023","journal-title":"Int. J. Hematol."},{"issue":"2","key":"10.1016\/j.leukres.2024.107596_bib65","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41409-018-0291-5","article-title":"Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation","volume":"54","author":"Inoue","year":"2019","journal-title":"Bone Marrow Transpl."},{"issue":"2","key":"10.1016\/j.leukres.2024.107596_bib66","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/hon.2712","article-title":"Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki transplant group experience","volume":"38","author":"Sakamoto","year":"2020","journal-title":"Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.leukres.2024.107596_bib67","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1038\/s41409-021-01432-5","article-title":"Treatment of relapsed aggressive adult T-cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation with mogamulizumab followed by lenalidomide","volume":"56","author":"Tamai","year":"2021","journal-title":"Bone Marrow Transpl."},{"issue":"3","key":"10.1016\/j.leukres.2024.107596_bib68","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hon.3115","article-title":"Lenalidomide treatment for recurrent adult T-cell leukemia\/lymphoma after allogeneic hematopoietic cell transplantation","volume":"41","author":"Tanaka","year":"2023","journal-title":"Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2024.107596_bib69","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/cas.15997","article-title":"Anti-HTLV-1 immunity combined with proviral load as predictive biomarkers for adult T-cell leukemia-lymphoma","volume":"115","author":"Yamada","year":"2024","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.leukres.2024.107596_bib70","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.13302","article-title":"Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia\/lymphoma in a pilot study","volume":"169","author":"Suehiro","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.leukres.2024.107596_bib71","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/cas.13948","article-title":"Maintenance of long remission in adult T-cell leukemia by tax-targeted vaccine: a hope for disease-preventive therapy","volume":"110","author":"Kannagi","year":"2019","journal-title":"Cancer Sci."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T14:16:18Z","timestamp":1732198578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624001620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":71,"alternative-id":["S0145212624001620"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107596","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy and allo-HSCT for young patients with aggressive ATL","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107596","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107596"}}